|

Lenvatinib plus TACE Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • Second Affiliated Hospital of Guangzhou Medical University1

Indications

  • Liver Disease1
  • Hepatocellular Carcinoma Non-resectable1
  • Liver Cancer1
  • Cancer1

Other1 trial

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.